Tau aggregation and its interplay with amyloid-β
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Neurofibrillary tangles and amyloid plaques constitute the hallmark brain lesions of Alzheimer's disease (AD) patients. Tangles are composed of fibrillar aggregates of the microtubule-associated protein tau, and plaques comprise fibrillar forms of a proteolytic cleavage product, amyloid-β (Aβ). Although plaques and tangles are the end-stage lesions in AD, small oligomers of Aβ and tau are now receiving increased attention as they are shown to correlate best with neurotoxicity. One key question of debate, however, is which of these pathologies appears first and hence is upstream in the pathocascade. Studies suggest that there is an intense crosstalk between the two molecules and, based on work in animal models, there is increasing evidence that Aβ, at least in part, exerts its toxicity via tau, with the Src kinase Fyn playing a crucial role in this process. In other experimental paradigms, Aβ and tau have been found to exert both separate and synergistic modes of toxicity. The challenge, however, is to integrate these different scenarios into a coherent picture. Furthermore, the ability of therapeutic interventions targeting just one of these molecules, to successfully neutralize the toxicity of the other, needs to be ascertained to improve current therapeutic strategies, such as immunotherapy, for the treatment of AD. Although this article is not intended to provide a comprehensive review of the currently pursued therapeutic strategies, we will discuss what has been achieved by immunotherapy and, in particular, how the inherent limitations of this approach can possibly be overcome by novel strategies that involve single-chain antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of glial cells may provide a link between the initial Aβ aggregation and the later development of tau aggregates,40”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxcity), suggesting that the presence of both pathological features are important to replicate the toxicity that occurs in human AD [106].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 2×
“Evidently, no mouse model is capable of fully recapitulating the neuropathological spectrum of the disease [72].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · cited 1×
“connected brain regions [15].”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cited by
Items 201–300 of 360
Zaghmi, A., Drouin-Ouellet, J., Brambilla, D., & Gauthier, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120461 · Cited by 13
Joseph, C. R. (2021) · Diagnostics · doi:10.3390/diagnostics11101888 · Cited by 15
Macroscopic modelling of Alzheimer’s disease: difficulties and challenges
Bertsch, M., Franchi, B., Raj, A., & Tesi, M. C. (2021) · Brain Multiphysics · doi:10.1016/j.brain.2021.100040 · Cited by 16
Anand, A., Khurana, N., Ali, N., Alasmari, A. F., Alharbi, M., Waseem, M., & Sharma, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1005972 · Cited by 21
“The pathological hallmarks of AD include deposition of amyloid beta (Aβ) plaques and tau neurofibrillary tangles (Nisbet et al., 2015; Morgese et al., 2017), decrease in brain acetylcholine (ACh), overexpression of acetylcholinesterase (AChE), and glutamate excitotoxicity (Francis, 2005).”
BackgroundEntropic Bristles Tune the Seeding Efficiency of Prion-Nucleating Fragments
Michiels, E., Liu, S., Gallardo, R. U., Louros, N. N., Mathelié‐Guinlet, M., Dufrêne, Y. F., Schymkowitz, J. W. H., Vorberg, I. M., & Rousseau, F. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.098 · Cited by 15
Tang, D., Sun, C., Yang, J., Fan, L., & Wang, Y. (2023) · Life · doi:10.3390/life13112203 · Cited by 17
“J et al. [61], that Aβ was also clearly shown to be able to lead to the phosphorylation In a study by Götz.”
BackgroundHoffman, A., Taleski, G., Qian, H., Wasek, B. L., Arning, E., Bottiglieri, T., Sontag, J., & Sontag, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180032 · Cited by 16
“We have previously reported 661 that MTHFR and/or dietary folate deficiencies also 662 increase the cortical and hippocampal accumulation 663 of pathologically phosphorylated tau proteins [33, 664 41], which play a critical role in mediating A neu665 rotoxicity in AD [19].”
BackgroundSoluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Povala, G., Bellaver, B., Bastiani, M. A. D., Brum, W. S., Ferreira, P. C. L., Bieger, A., Pascoal, T. A., Benedet, A. L., Souza, D. O., Araújo, R., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00712-3 · Cited by 14
“On the other hand, the importance of Aβ1‐42 isoform as a toxic amyloid specie has been extensively demonstrated (23-26).”
BackgroundResultPedrini, M., Iannielli, A., Meneghelli, L., Passarella, D., Broccoli, V., & Seneci, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051467 · Cited by 13
“, tau tangles [3]) or in the extracellular CNS space (i.”
BackgroundFalanga, A. P., Piccialli, I., Greco, F., D’Errico, S., Nolli, M. G., Borbone, N., Oliviero, G., & Roviello, G. N. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.16296 · Cited by 13
Timofeeva, A. M., Aulova, K. S., & Nevinsky, G. A. (2025) · Brain Sciences · doi:10.3390/brainsci15050486 · Cited by 17
“Further investigation is required to fully elucidate the complex interaction between plaques and tubules [3,4].”
Piersson, A. D., Ibrahim, B., Suppiah, S., Mohamad, M., Hassan, H. A., Omar, N. F., Ibrahim, M. I., Yusoff, A. N., Ibrahim, N., Saripan, M. I., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252883 · Cited by 15
Mammalian Models in Alzheimer’s Research: An Update
Sharma, H., Chang, K., Hulme, J., & An, S. S. A. (2023) · Cells · doi:10.3390/cells12202459 · Cited by 13
“The crosstalk between A β and NFT significantly increases the toxicity [230]; hence, the models displaying pathological characteristics of both A β and tau are important to study these interactions during AD progression and therapeutic intervention.”
BackgroundAnand, A., Sharma, N., & Khurana, N. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10s4.21330 · Cited by 16
Zhang, T., Pauly, T. A., & Nagel‐Steger, L. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.02.123 · Cited by 14
Preparation and in vitro activity of single chain antibodies against Alzheimer's disease
Fu, L., Zhang, Y., Zhang, X., Tian, W., Zhang, W., Jia, Y. X., & Zhang, L. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.07.009 · Cited by 13
Platelets: A new therapeutic target for neurological diseases
Wei, X., & Tang, X.-Q. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102874 · Cited by 12
Novel D–π-A type near-infrared fluorescent probes for the detection of Aβ 40 aggregates
Lv, G., Xu, Y., Yang, J., Li, W., Li, C., & Sun, A. (2020) · The Analyst · doi:10.1039/d0an01180k · Cited by 12
Exosomes and non-coding RNAs: bridging the gap in Alzheimer’s pathogenesis and therapeutics
Chunhui, G., You, Y., Chen, J., Luo, N., & Li, F. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01520-7 · Cited by 13
“However, a large body of evidence suggests that there are independent and synergistic mechanisms between Aβ and Tau (Karran and De Strooper 2022 ; Nisbet et al. 2015 ; Zhang et al. 2022 ).”
Ghotbeddin, Z., Tabandeh, M. R., Borujeni, M. P., Truski, F. F., Pour, M. R. Z. G., & Tabrizian, L. (2021) · Brain and Behavior · doi:10.1002/brb3.2078 · Cited by 13
“The pathological signs of AD are characterized by formation and accumulation of β- amyloid (Aβ) peptide as plaque in extracellular and deposition of Tau protein as neurofibrillary tangles as well as loss of neurons and synapses (Mondragón- Rodríguez et al., 2012; Nisbet et al., 2015).”
BackgroundReview of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20106 · Cited by 13
Sha, S., Xing, X.-N., Wang, T., Li, Y., Zhang, R., Shen, X., Cao, Y., & Qu, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.337054 · Cited by 16
“Activated kinases can phosphorylate dendritic tau, which then results in the migration of tau and Fyn into the dendritic spine (Nisbet et al., 2015).”
Co-aggregation of amyloidogenic proteins in age-related neurodegenerative diseases
Basha, S., Nadkarni, P. P., Pai, A. R., & Mahato, K. K. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103148 · Cited by 11
Insulin, Brain, Alzheimer’s Disease: New Evidence
Bulgakova, S. V., Иванович, Р. П., & Treneva, E. V. (2020) · Bulletin of Science and Practice · doi:10.33619/2414-2948/52/10 · Cited by 12
Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis
Whitfield, J. F., Rennie, K., & Chakravarthy, B. (2023) · Cells · doi:10.3390/cells12121618 · Cited by 12
Effects of acupuncture on patients with Alzheimer's disease
Shao, S., Tang, Y., Guo, Y., Tian, Z.-Y., Xiang, D., & Wu, J.-H. (2019) · Medicine · doi:10.1097/md.0000000000014242 · Cited by 7
Protective role of functional food in cognitive deficit in young and senile rats
Attia, H. N., & Ahmed, K. A. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000522 · Cited by 12
Role of Plant Polyphenols in Alzheimer’s Disease
Thenmozhi, A. J., Manivasagam, T., & Essa, M. M. (2016) · Advances in neurobiology · doi:10.1007/978-3-319-28383-8_9 · Cited by 15
Turnbull, M. T., & Coulson, E. J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160805 · Cited by 11
Bojić, T., Senćanski, M., Perović, V., Milićević, J. S., & Glišić, S. (2022) · Molecules · doi:10.3390/molecules27092626 · Cited by 11
“Currently, two licensed anti-AD drugs (galantamine and rivastigmine) are based on plant-derived natural products, in addition to the fact that natural products targeting tau aggregation in AD pathogenesis are also reported [38].”
BackgroundTherapeutic Effect of Erythropoietin on Alzheimer’s Disease by Activating the Serotonin Pathway
Shim, K.-H., Ha, S., Choung, J. S., Choi, J. I., Kim, D. Y., Kim, J., & Kim, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158144 · Cited by 10
“Accumulated Aβ plaques and neurofibrillary tangles induce various types of neurodegeneration and augment inflammatory response in a brain with AD [4,5].”
Leblhuber, F., Geisler, S., Ehrlich, D., Steiner, K., Kurz, K., & Fuchs, D. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220920090919 · Cited by 10
Kim, J. E., Kim, S.-W., Choi, M., Seong, J., & Lee, J. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317518813556 · Cited by 9
Plasma levels of Interleukin 18 but not amyloid-β or Tau are elevated in female depressive patients
Liu, F., Yang, L., Zheng, H. S., Zhou, Y., Chen, B.-B., Xu, H., Zhang, Y., & Shen, D. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2020.152159 · Cited by 12
He, Z., Zheng, L. P., Zhao, X., Li, X., Xue, H., Zhao, Q., Ren, B., Li, N., Ni, J., Zhang, Y., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-021-02938-1 · Cited by 10
“Tau protein and Aβ have complex and synergistic effects [7], and they mediate diverse toxic effects on neurons and synaptic plasticity [8].”
BackgroundRejecting the Alzheimer's disease vaccine development for the wrong reasons
Marciani, D. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.012 · Cited by 10
Numaguchi, Y., Tsukakoshi, K., Takeuchi, N., Suzuki, Y., Ikebukuro, K., & Kawano, R. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad437 · Cited by 10
“Various hypotheses have been reported as to the mechanism of neuronal toxicity of the A β 42 oligomer, including channel formation (15), mitochondrial damage (16), and an increase in hyperphosphorylated tau protein (17).”
Hadipour, E., Shahangian, S. S., & Mashayekhi, F. (2024) · Caspian Journal of Neurological Sciences · doi:10.32598/cjns.10.36.460.1 · Cited by 9
Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer’s Disease
Strużyńska, L., Adamiak, K., & Sidoryk‐Wȩgrzynowicz, M. (2026) · Biomolecules · doi:10.3390/biom16040595 · Cited by 9
“Activated AMPK phosphorylates dendritic tau, promoting its dissociation from microtubules and facilitating tau aggregation [108].”
Humpel, C. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335138 · Cited by 9
“However, this hypothesis is now surrounded by more and more controversy (Armstrong, 2014; Morris et al., 2014; Nisbet et al., 2015).”
BackgroundPlatelet TAU is Associated with Changes in Depression and Alzheimer's Disease
Sarg, B., Korde, D. S., Marksteiner, J., & Humpel, C. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705153 · Cited by 11
“Tau is a microtubule-associated protein and physiologically stabilizes and regulates axonal transport [25–28].”
BackgroundAnti-amnesic and Neuroprotective Potential of Genistein Against Alzheimer’s Disease
Singh, N. K., Verma, N. K., Gupta, J. K., & Raghav, J. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00452-0 · Cited by 12
“A major neuropathological condition of AD is associated with the accumulation of amyloid beta (Aβ) and hyperphosphorylation of Tau protein in the brain tissue (Nisbet et al. 2015; Goyal et al. 2023).”
Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease
Zahratka, J. A., Shao, Y. Y., Shaw, M. L., Todd, K. W., Formica, S. V., Khrestian, M., Montine, T. J., Leverenz, J. B., & Bekris, L. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.001 · Cited by 9
Nam, Y., Joo, B., Lee, J., Han, K., Ryu, K., Koh, Y. H., Kim, J., Koo, J. W., We, Y.-M., & Hoe, H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00192 · Cited by 12
“In addition, aggregation of tau causes dendritic spine loss and impairment of synaptic function by inducing the disassembly of microtubules (Thies and Mandelkow, 2007; Nisbet et al., 2015).”
BackgroundInflammasomes in Alzheimer’s Progression: Nrf2 as a Preventive Target
López-Hernández, R., de la Torre-Álamo, M. M., García-Bueno, B., Baroja‐Mazo, A., Fenoy, F. J., & Cuevas, S. (2025) · Antioxidants · doi:10.3390/antiox14020121 · Cited by 11
Prabha, S., Choudhury, A., Jawaid, T., Saeed, M. U., Thakur, S. C., & Hassan, M. I. (2025) · 3 Biotech · doi:10.1007/s13205-025-04413-3 · Cited by 8
“The activation of extrasynaptic N-methyl-D-aspartate receptors (NMDARs) by Aβ also causes calcium influx into the neuron and activates kinases (Nisbet et al. 2015).”
The Neuroprotective Potential of Ocimum Plant Species: Seasoning the Mind with Sweet and Holy Basil
Vasincu, A., Rusu, R.-N., Ababei, D. C., Bulea, D., Arcan, O. D., Vasincu, I. M., Chiriac, S. I. B., Popescu, I.-R., Bild, W., & Bild, V. (2025) · Nutrients · doi:10.3390/nu17172877 · Cited by 14
“Imbalances between A β production and clearance mechanisms lead to its accumulation, facilitating plaque formation and synaptic toxicity [18,21].”
Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
Nguyen, T.-D., Dang, L. N., Jang, J., & Park, S. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00631-0 · Cited by 9
Postupna, N. O., Latimer, C. S., Keene, C. D., Montine, K. S., Montine, T. J., & Darvas, M. (2018) · Neuromethods · doi:10.1007/978-1-4939-8739-9_17 · Cited by 7
New APOE-related therapeutic options for Alzheimer’s disease
Li, Z. (2019) · AIP conference proceedings · doi:10.1063/1.5085515 · Cited by 8
Acetyl-11-keto-β-boswellic acid derivatives effects on 5-lipoxygenase: In silico viewpoint
Bolbolian, S., Bozorgmehr, M. R., & Morsali, A. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.107464 · Cited by 7
Yerlikaya, P. O., Arısan, E. D., Gürkan, A. Ç., Okumus, O. O., Yazıcı, T. Y., Özbey, U., Kara, M., & Palavan-Ünsal, N. (2021) · Amino Acids · doi:10.1007/s00726-021-03027-2 · Cited by 9
Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 8
Rezaeisadat, M., Alizadeh, A., & Shahryari, E. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100755 · Cited by 6
Borrelidin from Saltern-Derived Halophilic Nocardiopsis sp. Dissociates Amyloid- β and Tau Fibrils
Shin, J., Yang, S., Du, Y. E., Park, K., Kim, D., Shin, D., Kim, J.-W., Kim, S.-H., Kim, Y. K., Shin, J., et al. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200247 · Cited by 7
“It is important to remove both proteins simultaneously due to an extensive crosstalk between A and tau during the development of AD pathology [7].”
BackgroundProtective Effects of Statins against Alzheimer Disease
Rezakhani, L., Salimi, Z., Zarei, F., Moradpour, F., Khazaei, M. R., Khazaei, M., & Pourjalili, M. (2023) · Ewha Medical Journal · doi:10.12771/emj.2023.e17 · Cited by 8
“Furthermore, inflammation may mediate a connection between early Aβ pathology and the subsequent development of NFTs [53].”
BackgroundChan, E. W. L., Yeo, E. T. Y., Wong, K. W. L., See, M. L., Wong, K. Y., Yap, J. K. Y., & Gan, S. Y. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210324124239 · Cited by 6
Veiveris, D., Kopūstas, A., Šulskis, D., Mikalauskaitė, K., Alsamsam, M. N., Tutkus, M., Smirnovas, V., & Žiaunys, M. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00130 · Cited by 6
“22 − 28 Combined with studies describing amyloid plaques in disease-affected brains having a heterogeneous protein content, 29 − 31 it is possible that heterotypic droplet formation plays a critical role in the onset and progression of several neurodegenerative disorders.”
Dabas, A., & Goyal, B. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00253 · Cited by 5
Scuderi, V., Turnaturi, R., Filice, S., Crispi, S., Natale, G. D., Sabatino, G., Ricciarelli, D., Fisicaro, G., Pappalardo, G., Magna, A. L., et al. (2025) · Small · doi:10.1002/smll.202503488 · Cited by 9
Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits
de Longprez, L., Gaillard, M., Decraene, C., Pérot, J., Keime, C., Nadkarni, N. A., Louçã, M., Jan, C., Liot, G., Aurégan, G., et al. (2025) · Brain · doi:10.1093/brain/awaf042 · Cited by 5
Dietary arachidonic acid: a Janus face actor in brain and Alzheimer’s disease?
Pinchaud, K., Maguin‐Gaté, K., & Olivier, J. L. (2018) · OCL · doi:10.1051/ocl/2018033 · Cited by 6
“Tau protein physiologically associates to microtubules in mature neurons and play an important role in neuronal signalling and axonal transport (Nisbet et al., 2015; Chong et al., 2018).”
BackgroundSmall molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook
Hajam, I. B., Ahanger, I. A., Rasool, U., & Dar, T. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.017 · Cited by 5
Hudák, A., & Letoha, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094037 · Cited by 6
“Once inside, these aggregates are transported to early endosomal compartments, where they may fibrillate further, contributing to the formation of amyloid plaques and tau tangles, hallmark features of AD [130].”
Conformation-Specific Association of Prion Protein Amyloid Aggregates with Tau Protein Monomers
Žiaunys, M., Mikalauskaitė, K., Krasauskas, L., & Smirnovas, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119277 · Cited by 4
“Some of the observed cross-interactions involved proteins/peptides related to widespread neurodegenerative disorders: amyloid-beta with alpha-synuclein [9], Tau [10,11] and prion protein [12], as well as alpha-synuclein with prion protein [13] and Tau [14,15].”
BackgroundAlaziqi, B. H., Beckitt, L., Townsend, D. J., Morgan, J., Price, R., Maerivoet, A., Madine, J., Rochester, D. L., Akien, G. R., & Middleton, D. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c01281 · Cited by 11
Exploring the Impact of C‐Terminal Based Pentapeptides on the Disassembly of Aβ42 Fibrils
Kaur, A., Mankoo, O. K., Rani, D., Priyadarshi, N., Goyal, D., Singhal, N. K., & Goyal, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202400486 · Cited by 5
Development of an Effective Alzheimer’s Vaccine
Marciani, D. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00011-3 · Cited by 5
Dávila-Bouziguet, E., Casòliba-Melich, A., Fabra, G. T., Galera-López, L., Ozaita, A., Maldonado, R. J., Ávila, J., Delgado-Garcia, J. M., Gruart, A., Soriano, E., et al. (2021) · Brain · doi:10.1093/brain/awab319 · Cited by 4
Etemadi, A., Hemmati, S., Shahrivar‐Gargari, M., Abibiglue, Y. T., Bavili, A. S., Hamzeh‐Mivehroud, M., & Dastmalchi, S. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300075 · Cited by 5
Sleep and Memory Formation in Drosophila
Dissel, S., & Shaw, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21033-x · Cited by 4
Whitfield, J., Chiarini, A., Prà, I. D., Armato, U., & Chakravarthy, B. (2015) · Cells · doi:10.3390/cells4030253 · Cited by 4
Singh, H., Thakur, S., Sahajpal, N., Singh, H., Singh, A., Sohal, H. S., & Jain, S. K. (2020) · Current Drug Delivery · doi:10.2174/1567201817666200512103402 · Cited by 4
Latina, V., Introna, M. D., Malerba, F., Florio, R., Balzamino, B., Natale, G. D., Sciacca, M., Pappalardo, G., Micera, A., Pignataro, A., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02022-y · Cited by 3
“1,8,9); (ii) therapeutically-targetable NH 2 htau early (at pre-deposit stage) synergizes with soluble forms of Aβ and its 12 A12 mAb-mediated depletion negatively interferes with its aggregation pathway leading in older animals to decrease of the most toxic, prefibrillar oligomers (A11-positive)…”
Noh, B., Lee, H.-J., Lee, J., Lee, J., Joo, B., Jung, Y., Park, M., Kang, S., Oh, S., Hwang, J.-W., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01162 · Cited by 5
Kashif, O., & Said, M. (2025) · Discover Medicine · doi:10.1007/s44337-025-00455-x · Cited by 4
“The hallmark features include two types of pathological protein aggregates: extracellular accumulation of Aβ peptides forming senile plaques and intracellular aggregation of hyperphosphorylated Tau protein resulting in NFTs [9].”
Kim, S., Kumar, V., Shin, S. J., Nam, Y., Park, Y. H., Jang, S., Park, J. Y., Kim, D. H., & Moon, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118876 · Cited by 4
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Protein and Peptide Letters · doi:10.2174/0109298665348075241121071614 · Cited by 3
S100A9 inhibits and redirects prion protein 89-230 fragment amyloid aggregation
Žiaunys, M., Šulskis, D., Mikalauskaitė, K., Sakalauskas, A., Sniečkutė, R., & Smirnovas, V. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110087 · Cited by 3
Phospho-tau 181 is enhanced in saliva and plasma of edentulous patients: a first sign of dementia?
Zürcher, C., Defrancesco, M., & Humpel, C. (2025) · Frontiers in Oral Health · doi:10.3389/froh.2025.1627681 · Cited by 3
Immunohistochemical detection of the delayed formation of nonfibrillar large amyloid‐β aggregates
Ochiishi, T., Itakura, A., Liu, L., Akatsu, H., Kohno, H., Nishimura, M., & Yoshimune, K. (2016) · Genes to Cells · doi:10.1111/gtc.12332 · Cited by 3
Jones, C. L., Marsden, E. A., Nevin, A. C., Kariuki, B. M., Bhadbhade, M. M., Martin, A. D., & Easun, T. L. (2017) · Royal Society Open Science · doi:10.1098/rsos.171064 · Cited by 3
Darabi, M. K., Rafeeinia, A., Pezeshki, S. P., Nazeri, Z., Kheirollah, A., & Cheraghzadeh, M. (2025) · The FASEB Journal · doi:10.1096/fj.202401167rr · Cited by 2
Dabas, A., & Goyal, B. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp03330b · Cited by 2
NRN1 may Modulate Tau Phosphorylation and Neuronal Apoptosis in AD via the PIGU-CASP3 Axis
Cheng, W., Zhang, J., Zhu, H., Wang, Z., Li, M., Wang, J., Fu, H., Zhang, Y., Gao, Y., Chen, C., et al. (2025) · Current Alzheimer Research · doi:10.2174/0115672050361366250328040542 · Cited by 2
Joshi, D., Kumar, B., Singhal, M., Bhargava, S., & Ankur, K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230321121939 · Cited by 3
Lin, Q., Bian, W., Wang, D., Ming, Z., Zhang, Y., Zhang, L., & Fu, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221088 · Cited by 2
“Additionally,throughtheircom-binedeffects,A (cid:2) and p-Tau damage the transcription of genes involved in synaptic function [36].”
Veselov, V. V., Николаевич, Е. Н., Trukhan, V. M., Zvyagin, A. V., & Nosyrev, A. E. (2023) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-023-02845-w · Cited by 3
Walia, A., Shew, M. A., Durakovic, N., Herzog, J. A., Cirrito, J. R., Yuede, C. M., Wick, C. C., Manis, M., Holtzman, D. M., Buchman, C. A., et al. (2024) · Otolaryngology · doi:10.1002/ohn.942 · Cited by 2
“52 Future studies should determine the extent to which these processes may be mirrored in the inner ear.”
Biophysics-Based Data Assimilation of Longitudinal Tau and Amyloid-$$\beta $$ PET Scans
Wen, Z., Ghafouri, A., & Biros, G. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-72083-3_2 · Cited by 5
Sen, S., Meur, S., Nandi, G., & Karati, D. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100171 · Cited by 2
Immunotherapy in Alzheimer’s Disease
Gupta, J., & Hoque, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_14 · Cited by 2
Saffron in Phytotherapy: Pharmacological Properties and Medicinal Uses
Zouagui, R., & Sbabou, L. (2022) · Compendium of plant genomes · doi:10.1007/978-3-031-10000-0_15 · Cited by 5
Amyloid Beta: The Foremost Protagonist in Alzheimer's Disease
Anand, A., Sharma, N., Gulati, M., & Khurana, N. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch011 · Cited by 2
Kilinc, D., Vreulx, A.-C., Mendes, T., Flaig, A., Coelho, D. M., Verschoore, M., Demiautte, F., Amouyel, P., Bank, N.-C. B., Eysert, F., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.20.884205 · Cited by 2
“…worldwide, is characterized by two types of brain lesions: (i) neurofibrillary degeneration due to the intracellular aggregation of abnormally hyperphosphorylated tau protein and (ii) amyloid plaques resulting from the extracellular accumulation of amyloid beta (Aβ) peptides (Nisbet et al., 2015).”
BackgroundTheranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than A β [49,51], making it a promising agent for targeted therapy delivery.”
Zhang, Y., Xu, D., Zhang, X., Zhou, W., Zhang, L., & Lin, Q. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250160 · Cited by 1
Hu, Q., Liu, C., Tan, J., Wang, J., Yang, H., Liu, Y., Mao, H., Jiang, Z., Feng, X., & Tao, X. (2025) · Pharmaceuticals · doi:10.3390/ph18060809 · Cited by 1
“Nanoparticles can enhance the solubility of insoluble drugs due to their large specific surface area [15–17].”
Chemical Approaches for Array Based Detection of Amyloids
Simon, P. M., Xu, Y., & Kaur, A. (2025) · Advanced Sensor Research · doi:10.1002/adsr.202500108 · Cited by 1
Emad, M., Waheed, R., Mostafa, Z., Darwish, S. S., Purgatorio, R., Miniero, D. V., Palma, A. D., Cheng, T., Chen, Y., Gabr, M. T., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00802f · Cited by 3
Metadata
- Authors
- Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- UNSW Sydney (AU)
- Corresponding author
- Nisbet, Rebecca M.
- Götz, Jürgen
- Venue
- Acta Neuropathologica
- Published
- 2014-12-10
- Volume
- 129
- Issue
- 2
- Pages
- 207-220
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4305093
- OpenAlex
- W2007787335
- Cited by
- 359
- References
- 114
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 20 · 2023: 22 · 2022: 49 · 2021: 41 · 2020: 33 · 2019: 44 · 2018: 32 · 2017: 26 · 2016: 31 · 2015: 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP13300101932)
- National Health and Medical Research Council (1003150, 1037746)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau aggregation, amyloid-beta, Alzheimer's disease, neurofibrillary tangles, amyloid plaques, tau oligomers, amyloid-beta oligomers, neurotoxicity, Fyn, immunotherapy, single-chain antibody, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Humans, Synapses, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.